IRE ELiT and Telix Pharmaceuticals enter French Distribution Agreement for Prostate Cancer Imaging
We are proud to announce today that we have signed a distribution agreement with Advanced Nuclear Medicine Ingredient S.A., a subsidiary of Telix Pharmaceuticlas Limited, for the distribution of the metastatic prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical cold kit complementary of its GalliAd 68Ge/68Ga new generation generator, specifically designed for cold kits preparation.
Under the terms of the agreement, IRE ELiT has been designated as the exclusive distributor of the TLX591-CDx in France and the French overseas territories, both during the initial period of Temporary Operating Authorization and after the granting of a Marketing Authorization (MA) on the European market in 2021.
To date, TLX591-CDx does not have a marketing authorization.
Press release available here.